Diabetes

The company also will establish a $35 out-of-pocket price cap for for all patients with commercial insurance that use Latnus

Significant differences in the use of insulin pump and/or CGM technology were noted based on demographic and socioeconomic factors

Leading health organizations are urging those with diabetes and other chronic conditions to get the influenza vaccine.

Not only were people with newly diagnosed type 2 diabetes less likely to develop dementia if they took pioglitazone, but the benefit was stronger among patients with a history of ischemic heart disease or stroke.

Two studies found digital therapeutics can help patients manage their type 2 diabetes effectively regardless of race or ethnicity.

A smartphone app is associated with improvement in HbA1c levels, but physician involvement with patients and other factors may be the benefit.

Pharmaceutical companies are experiencing supply chain disruptions and shortages because of the popularity of diabetes drugs used for weight loss.

Results of a phase 3 clinical trial represent another avenue of treatment for children and adolescents living with type 2 diabetes.

According to the study, vitamin D was beneficial in decreasing the risk for diabetes and increasing the rate of regression back to normal glucose regulation.

Mallya can provide convenience for insulin pen users; however, it has yet to be released in the United States.

The new medication reduces HbA1c and improves glycemic control as an adjunct to diet and exercise.

Pharmaceutical makers, price managers out of control with ‘necessary drug’ for millions, Attorney General says.

The American Diabetes Association has updated their Standards of Care, which includes new hypertension guidelines, medication guidance, and emphasis on weight loss.

Eli Lilly and Company and Boehringer Ingelheim announced their SGLT2 inhibitor, empagliflozin, was associated with statistically significant reductions in HbA1c relative to placebo therapy among a population of pediatric patients with type 2 diabetes in the DINAMO trial.

The program Project Power helps give children and their families the tools to reduce disparities found with diabetes.

The Medicare Part D Senior Savings Model — a CMS effort to test $35 copays for insulin — led to lowered total costs for beneficiaries.

By offering resources such as free samples and generic alternatives, pharmacists can help patients lower costs.

Dexcom expects the device to launch in the United States early next year.

Diabetes self-management education and diabetes prevention programs can improve patient outcomes including mental health and HbA1C.

New research adds more evidence of Black patients facing disparities in diabetes care.

European research examines antibiotic exposure and its potential impact on future type 2 diabetes risk.

Take a look back at our most popular diabetes coverage for 2022.

New research indicates that glucose monitoring could lead to lifestyle changes during prediabetes.

Insulin glargine-aglr received initial FDA approval in December 2021.

Drs Meece and Goldman share final thoughts on the overall current and future treatment landscape for diabetes.

Addressing fears surrounding insulin injections through education may positively impact treatment adherence.

Experts provide suggestions for optimizing patient education by encouraging patient engagement.

Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP, discusses topics to address with patients to ensure appropriate self-administration of insulin.

According to a study, use is linked to a lower prevalence of age-related macular degeneration in European populations.

Dr Meece navigates insulin therapy education and ensuring patient adherence.